OWCP (OWC Pharmaceutical Research) EBIT: $-9.73 Mil (TTM As of Sep. 2019)


What is OWC Pharmaceutical Research EBIT?

OWC Pharmaceutical Research OWCP -90.00% EBIT is $-9.73 Mil as of Sep. 2019.

OWC Pharmaceutical Research's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2019 was $-0.59 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2019 was $-9.73 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. OWC Pharmaceutical Research's annualized ROC % for the quarter that ended in Sep. 2019 was -563.75%. OWC Pharmaceutical Research's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 was -2,863.41%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

OWC Pharmaceutical Research  (OTCPK:OWCP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

OWC Pharmaceutical Research's annualized ROC % for the quarter that ended in Sep. 2019 is calculated as:

ROC % (Q: Sep. 2019 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2019 ) + Invested Capital (Q: Sep. 2019 ))/ count )
=-2.348 * ( 1 - 0% )/( (0.498 + 0.335)/ 2 )
=-2.348/0.4165
=-563.75 %

where

Invested Capital(Q: Jun. 2019 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.335 - 0.104 - ( 1.84 - max(0, 0.516 - 2.249+1.84))
=0.498

Invested Capital(Q: Sep. 2019 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.773 - 0.286 - ( 1.465 - max(0, 0.543 - 1.695+1.465))
=0.335

Note: The Operating Income data used here is four times the quarterly (Sep. 2019) data.

2. Joel Greenblatt's definition of Return on Capital:

OWC Pharmaceutical Research's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2019 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2019  Q: Sep. 2019
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2.348/( ( (0.086 + max(-0.081, 0)) + (0.078 + max(-0.287, 0)) )/ 2 )
=-2.348/( ( 0.086 + 0.078 )/ 2 )
=-2.348/0.082
=-2,863.41 %

where Working Capital is:

Working Capital(Q: Jun. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.409) - (0.104 + 0.1 + 0.286)
=-0.081

Working Capital(Q: Sep. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.23) - (0.286 + 0 + 0.231)
=-0.287

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2019) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

OWC Pharmaceutical Research's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2019 )
=-9.727/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OWC Pharmaceutical Research EBIT Related Terms

OWC Pharmaceutical Research EBIT Historical Data

* Premium members only.

The historical data trend for OWC Pharmaceutical Research's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OWC Pharmaceutical Research EBIT Chart

OWC Pharmaceutical Research Annual Data
Trend Dec08 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EBIT
Get a 7-Day Free Trial Premium Member Only -5.07 -1.65 -2.10 -4.55 -10.26

OWC Pharmaceutical Research Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.67 -7.64 -0.78 -0.72 -0.59

OWCP vs PARNF, CANB, CXUS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, OWC Pharmaceutical Research's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OWC Pharmaceutical Research EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OWC Pharmaceutical Research's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where OWC Pharmaceutical Research's EV-to-EBIT falls into.


OWC Pharmaceutical Research EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-9.73 Mil mean?
OWC Pharmaceutical Research (OWCP) has a EBIT of $-9.73 Mil as of Sep. 2019. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on OWC Pharmaceutical Research.
Is OWC Pharmaceutical Research's EBIT too high?
OWC Pharmaceutical Research's current EBIT is $-9.73 Mil.
How does OWC Pharmaceutical Research's EBIT compare to PARNF and CANB?
OWC Pharmaceutical Research's EBIT of $-9.73 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on OWC Pharmaceutical Research. OWC Pharmaceutical Research's current EBIT is $-9.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OWC Pharmaceutical Research stock overvalued right now?
OWC Pharmaceutical Research (OWCP) has a current EBIT of $-9.73 Mil. The current EBIT is $-9.73 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For OWC Pharmaceutical Research (OWCP), the current EBIT is $-9.73 Mil as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OWC Pharmaceutical Research Business Description

Address 2 Ben Gurion Street, Ramat Gan, ISR, 4514760
OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.